• M S Anker, S Hadzibegovic, and S von Haehling.
• Medizinische Klinik für Kardiologie, Charité - Campus Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, Deutschland. markus.anker@charite.de.
• Internist (Berl). 2020 Nov 1; 61 (11): 1120-1124.

AbstractAs a result of the continuous development of modern cancer treatment, more cancer patients can be cured every year. However, since many patients experience cardiovascular problems before, during and after their cancer treatment, cardio-oncology is becoming increasingly important. Numerous therapies can cause cardiotoxicity, such as chemotherapy, immunotherapy, antibody therapy and radiotherapy. If these remain undetected, the patient may develop, e.g. heart failure or severe heart valve damage. The broad spectrum of cardiovascular comorbidities has become an immense challenge for cardiologists and oncologists. Cardio-oncology also deals with the effects that cancer has on the cardiovascular system. New research indicates that the tumor itself also has direct negative effects on the heart, mediated by messenger substances. Therefore, it is important to understand which cancer patients are at increased cardiovascular risk, thereby enabling the development of new therapeutic approaches in the long term to maintain mobility and improve patient prognosis.

18 keywords...

hide…